Exact FDA event identifier

Event 77757

1 recalled-product record grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: July 12, 2017
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

Testosterone Cypionate + Progesterone, 200 mg/ 2.5 mg/mL ,10 mL amber glass vials, Rx Only, Compounded by AXIA Pharmaceutical, Los Angeles, CA 90025

D-1040-2017

Recall number: D-1040-2017
Initiated: July 12, 2017
Classification: Class II
Status: Terminated
Recalling firm: Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
Quantity: 120 vials

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

Lot # 03022017+44906; BUD 08/29/17

Distribution pattern

There were only one customer in California